Conditionally active, therapeutic lymphotoxin beta receptor (LTBR) agonist bispecific antibodies for induction of tertiary lymphoid structures in the treatment of solid tumors

Lewandowska M; Demircioglu F; Penfold L; Riddle R; Sirohi S; Laurent F; Brown R; Bains S; Bevan D; Stanley E; Pignatelli J; Legg J; Jupp R

Mestag Therapeutics Limited, Chesterford Research Park, Cambridge CB10 1XL, United Kingdom

Abstract #LB123

Presence of TLS Correlates with Better Survival
Examples from NSCLC, Melanoma, HNSCC and ESCC



M300 Bispecific Antibody: Conditional Activation of LTBR

References

a l